Q2 2026 earnings snapshot

Twist Bioscience (TWST) has just posted Q2 2026 results with revenue of US$110.7 million and a basic EPS loss of US$0.71, alongside trailing twelve month revenue of US$409.5 million and a trailing EPS loss of US$1.34, giving investors a clear read on both the latest quarter and the recent run rate. Over the past six reported quarters, revenue has moved from US$88.7 million in Q1 2025 to US$110.7 million in Q2 2026, while quarterly basic EPS has ranged from a loss of US$0.66 in Q2 2025 to a profit of US$0.34 in Q3 2025 before returning to a loss of US$0.71 in the latest quarter, so the top line has scaled up while profitability has remained uneven. The result is a quarter where revenue momentum is visible but margins and consistency of earnings are still front and center for anyone watching the stock at US$56.70.

See our full analysis for Twist Bioscience.

With the headline numbers on the table, the next step is to see how this mix of growing sales and ongoing losses lines up with the prevailing narratives around Twist Bioscience and where those stories might need updating.

TTM losses of US$81 million keep profitability in focus

• On a trailing twelve month basis, Twist Bioscience reported revenue of US$409.5 million and a net loss of US$81.3 million, compared with individual quarterly net losses that have ranged from US$27.1 million to US$44.0 million over the last six reported quarters.
• Consensus narrative talks about expanding margins and a path toward adjusted EBITDA breakeven. However, the recent TTM loss of US$81.3 million and Q2 2026 EPS loss of US$0.71 keep the gap to actual profitability wide, which means the story of improving efficiency is still playing out against ongoing negative earnings.

Revenue growth outpacing market expectations

• Revenue over the last six reported quarters has moved from US$88.7 million in Q1 2025 to US$110.7 million in Q2 2026, and analysts are forecasting around 13.7% annual revenue growth compared with the 11.2% market benchmark cited.
• Bulls argue that broadening use cases in synthetic biology and AI driven drug discovery can support compounding growth, and the current TTM revenue base of US$409.5 million alongside the forecast 13.7% annual growth rate is a central part of the bullish thesis even while the company remains loss making today.
• Supporters point to expanding demand for DNA based products as a reason revenue could continue to grow from the current US$409.5 million level.
• The fact that forecast revenue growth sits above the 11.2% market benchmark is a concrete data point bulls lean on when they talk about Twist Bioscience having a wider opportunity than a typical stock.

Bulls often frame this kind of revenue trend as the foundation for a long term growth story, so if you want to see how that optimistic view connects these numbers to potential upside, check out the 🐂 Twist Bioscience Bull Case

P/S of 8.6x vs peers at 19.8x

• The stock trades on a P/S of 8.6x compared with a peer average of 19.8x and a US Biotechs industry average of 10.8x, while the share price is US$56.70 and analysts cite a consensus target of US$61.88, so valuation is sitting below both peers and the stated target level.
• Bears highlight that analysts do not expect profitability over the next three years and that recent insider selling adds another risk flag. This cautious view ties directly to the ongoing TTM net loss of US$81.3 million and the history of quarterly EPS staying in loss territory in five of the last six quarters even with the lower P/S multiple.
• Critics point out that a comparatively lower P/S of 8.6x can still be consistent with risk if the company stays unprofitable, which is exactly what the three year loss forecasts suggest.
• The combination of continued losses and insider selling over the past three months is often cited by cautious investors as a reason the stock might deserve to trade below the 19.8x peer P/S, despite its revenue growth profile.

For a closer look at why some investors remain cautious despite revenue growth, and how they see the downside case building from these numbers, have a look at the 🐻 Twist Bioscience Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Twist Bioscience on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Seeing a mix of cautious and optimistic signals around Twist Bioscience, it can be helpful to review the underlying data yourself and act promptly while sentiment is still forming, starting with a clear view of the 2 key rewards and 2 important warning signs

See What Else Is Out There

Twist Bioscience is still posting sizeable TTM losses of US$81.3 million, with uneven EPS and no analyst expectation of profitability over the next three years.

If you want ideas that put more emphasis on financial resilience and steadier earnings profiles, check out the 72 resilient stocks with low risk scores to compare alternatives while this stock's story is still developing.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.